At US$83.95, Is IRADIMED CORPORATION (NASDAQ:IRMD) Worth Looking At Closely?
IRADIMED CORPORATION (NASDAQ:IRMD), might not be a large cap stock, but it saw significant share price movement during recent months on the NASDAQGM, rising to highs of US$97.03 and falling to the lows of US$81.87. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether IRADIMED's current trading price of US$83.95 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at IRADIMED’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.
What's The Opportunity In IRADIMED?
According to our valuation model, IRADIMED seems to be fairly priced at around 6.10% above our intrinsic value, which means if you buy IRADIMED today, you’d be paying a relatively fair price for it. And if you believe that the stock is really worth $79.13, then there isn’t really any room for the share price grow beyond what it’s currently trading. In addition to this, IRADIMED has a low beta, which suggests its share price is less volatile than the wider market.
View our latest analysis for IRADIMED
Can we expect growth from IRADIMED?
Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. IRADIMED's earnings over the next few years are expected to increase by 33%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value.
What This Means For You
Are you a shareholder? IRMD’s optimistic future growth appears to have been factored into the current share price, with shares trading around its fair value. However, there are also other important factors which we haven’t considered today, such as the track record of its management team. Have these factors changed since the last time you looked at the stock? Will you have enough confidence to invest in the company should the price drop below its fair value?
Are you a potential investor? If you’ve been keeping an eye on IRMD, now may not be the most optimal time to buy, given it is trading around its fair value. However, the positive outlook is encouraging for the company, which means it’s worth further examining other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.
Since timing is quite important when it comes to individual stock picking, it's worth taking a look at what those latest analysts forecasts are. At Simply Wall St, we have the analysts estimates which you can view by clicking here.
If you are no longer interested in IRADIMED, you can use our free platform to see our list of over 50 other stocks with a high growth potential.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.